4 Top Biotech Stocks With Big Upcoming Catalysts
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
BioMarin Pharmaceutical may have missed out on the Trump rally, but it might not be too late to catch a ride on the wave, at least according to one analyst.
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
The top analyst upgrades, downgrades and initiations seen on Monday morning include GoPro, Randgold Resources, Teva Pharmaceutical, Time Warner, Waste Management.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
BioMarin Pharmaceutical is ready to break above the $1 billion revenue barrier in 2016, a feat that marks a major hurdle for many biotech and emerging pharmaceutical companies.